ImmuneWorks, Inc
We are developing a phase II ready asset for idiopathic pulmonary fibrosis, a deadly lung disease with an addressable market of $2.8bn.
- Stage Product In Development
- Industry Biotechnology
- Location United States
- Currency USD
- Founded January 2006
- Employees 5
- Website immuneworks.com
Company Summary
We are developing an asset for the treatment of idiopathic pulmonary fibrosis (IPF) a deadly lung disease with 3-year mean survival after diagnosis and for which there are no approved drugs for the 125,000 U.S. IPF patients. ImmuneWorks asset was safe and signals of its ability to halt lung function decline were seen in a phase 1 clinical trial. We are raising capital to conduct a Phase 2 clinical trial that will lead to an exit via trade sale.
Team
-
Wade LangePresident & CEO
-
David Wilkes, MDFounder and Chief Science Officer
-
Michael Klemsz, PhDFounder and Vice President of Research
-
Terrence Chew, MDHead of Clnical Development and Regulatory Affairs
-
Katia Rothhaar, PhDDirector, Research Operations
Advisors
-
General Business: Ice Miller; Intellectual Property: Cooley, LLPLawyerUnconfirmedMilestone AdvisorsAccountantUnconfirmed
Previous Investors
-
Indiana Seed Fund IUnconfirmedIndiana Economic Development CorporationUnconfirmedBohemian Asset ManagementUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.